



Digestive Diseases Research Seminar

Presented by

Yale School of Medicine's Department of Internal Medicine,
Section of Digestive Diseases

“Prognostic molecular signatures for exploration of liver cancer therapeutics and chemoprevention”

Yujin Hoshida, MD, PhD

Associate Professor of Medicine

Division of Liver Diseases, Hematology and Medical Oncology

Tisch Cancer Institute

Icahn School of Medicine at Mount Sinai

Tuesday, April 10, 2018

TAC S-247

300 Cedar Street

5:00 - 6:00 pm

Host: Yasuko Iwakiri, PhD

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, and staff, and local GI physicians. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** Therapeutic development for liver cancer. Prevention of liver cancer. **Learning Objectives:** Strategy to identify candidate therapeutics based on analysis of clinical specimens. Strategy to identify candidate liver cancer chemopreventive therapies. Personalized liver cancer patient management using molecular information. **Faculty Disclosures:** Y Hoshida - Allergan, Kyowa Kin, Abbvie, Astra Zeneca, Gilead, Enanta: research grants and principal investigator. Boehringer Ingelheim: honorarium speaker. Y Iwakiri - None. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**